Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

Takeda Showcases Broadened Oncology Portfolio Through Data Presentations at Upcoming Medical Meetings

(Takeda) May 24, 2017 - Takeda to share data at the American Society of Clinical Oncology (ASCO) Annual Meeting, the Congress of the European Hematology Association (EHA) and the International Conference on Malignant Lymphoma (ICML); data underline Takeda’s mission to address the unmet needs of patients across a wide range of cancers.

read corporate press release

Gut Bugs Signal Success of Bone Marrow Transplant

(MedPage Today) May 24, 2017 - Patients who harbored a certain kind of bacteria within their intestinal tract seemed to have a lower risk of seeing their hematologic malignancies return after allogeneic hematopoietic-cell transplantation (allo-HCT), researchers reported.

read article (free registration required)

Possible Link Between Platelets and Cancer Risk, Though Further Work Needed

(Cancer Research UK/Press Association) May 25, 2017 - A possible link between cancer and the levels of a component of blood, called platelets, should be investigated further, according to a new study.

read article

University of Kansas Cancer Center Partners with Dana-Farber Cancer Institute and the Leukemia & Lymphoma Society to Offer Innovative Blood Cancer Clinical Trials

(KU Medical Center) May 24, 2017 - The University of Kansas Cancer Center has announced that it will join a consortium with the Dana-Farber Cancer Institute, in collaboration with The Leukemia & Lymphoma Society (LLS), to bring clinical trials testing innovative blood cancer therapies to Kansas City.

read press release

Lack of Access to Transfusions Limits Hospice Use By Blood Cancer Patients

(Dana-Farber) May 22, 2017 - A new survey finds that doctors would refer more patients with incurable blood cancers to hospice for end-of-life care if they could receive transfusions, which are generally not available because of hospice reimbursement policies.

read press release

Aprea Therapeutics Announces First Patients Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Myelodysplastic Syndrome

(TheStreet) May 23, 2017 - Aprea Therapeutics announced today that the first patient was enrolled in the Phase Ib/II clinical study of APR-246 in myelodysplastic syndrome (MDS).

read article

BioLineRx Announces Regulatory Submission for Phase 1b Trial of BL-8040 in Combination with Atezolizumab in AML

(TheStreet) May 22, 2017 - BioLineRx Ltd., a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the filing of regulatory submissions required to commence a Phase 1b trial for BL-8040 in combination with atezolizumab (Tecentriq®), Genentech, a member of the Roche Group's anti-PDL1 cancer immunotherapy, for the maintenance treatment of patients with acute myeloid leukemia (AML) who have achieved complete response following induction therapy.

read article

First Drug for Cachexia -- Cheers, Then Rejection

(Medscape Medical News) May 19, 2017 - When the clinical trial data were first presented at a European meeting, they were welcomed enthusiastically, but they didn't make the cut for approval.

read article (free registration required)

Three More Biosimilar Rituximab Products in Europe

(Medscape Medical News) May 19, 2017 - Three more biosimilar versions of the monoclonal antibody rituximab have been recommended for approval in Europe, having been found to be "highly similar" to the reference product, rituximab (MabThera, Roche).

read article (free registration required)

Why Fewer Blood Cancer Patients Receive Hospice Care

(Wiley) May 22, 2017 - Research has shown that patients with blood cancers are less likely to enroll in hospice care than patients with solid cancers, and the findings from a national survey suggest that concerns about the adequacy of hospice may prevent blood cancer specialists from referring their patients.

read press release

Refusal of the Marketing Authorisation for Masipro (masitinib)

(EMA) May 19, 2017 - On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Masipro, intended for the treatment of systemic mastocytosis.

read article

A Small Boston Biotech Is At The Heart Of A Groundbreaking Approach To Tackling Cancer

(Business Insider) May 21, 2017 - On Wednesday, Agios came out with new data on its phase 1/2 trial, which will be presented at the American Society of Clinical Oncology annual conference.

read article

How a Drug Ad Made Its Way Into ‘General Hospital’

(STAT) May 18, 2017 - Incyte’s move to bake a disease-awareness campaign into a TV show looks to be an industry first.

read article

7 Areas to Watch From the ASCO Abstracts

(BioPharma Dive) May 18, 2017 - If the annual meeting of the American Association for Cancer Research (AACR) in March put IDO inhibition on the map in immuno-oncology, next month’s mega-conference hosted by the American Society for Clinical Oncology (ACSO) could push interest even higher.

read article

A Father's Plea: The FDA Needs To Make Sure That Juno's Lethal Disaster Isn't Repeated

(Endpoints News) May 19, 2017 - The FDA never has publicly explained just why it decided to lift a clinical hold on Juno’s lead CAR-T drug JCAR015 just days after the stunning news that the trial was being halted after three patients taking the cell therapy died of a cerebral edema. But then, it never does, citing secrecy rules that frequently keep regulators silent.

read article

European Medicines Agency Validates Application for Bristol-Myers Squibb’s Sprycel (dasatinib) in Children with Chronic Myelogenous Leukemia

(BMS) May 19, 2017 - Bristol-Myers Squibb Company today announced that the European Medicines Agency (EMA) validated its grouped Type II variation/Extension of Application for Sprycel (dasatinib) to treat children and adolescents aged 1 year to 18 years with chronic phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) and to include the powder for oral suspension. Validation of the application confirms the submission is complete and begins the EMA’s centralized review process.

read corporate press release

GlycoMimetics' GMI-1271 Receives FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia

(GlycoMimetics) May 17, 2017 - GlycoMimetics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for treatment of adult relapsed/refractory acute myeloid leukemia (AML) to the company's drug candidate GMI-1271, an E-selectin antagonist currently being evaluated in the Phase 2 portion of a Phase 1/2 clinical trial in patients with AML.

read corporate press release

Diplomat Now Dispensing RYDAPT® (Midostaurin) for Acute Myeloid Leukemia

(Morningstar) May 18, 2017 - Diplomat Pharmacy, Inc., is now dispensing RYDAPT® (midostaurin), recently approved by the Food and Drug Administration.

read article

South Korea's Celltrion Sees Rapid Take-Off For Roche Drug Copy

(Reuters) May 15, 2017 - The South Korean company behind the first cut-price copy of Roche's blockbuster biotech cancer drug Rituxan anticipates rapid sales growth in Europe as healthcare providers embrace the cheaper medicine.

read article

Combo Therapies Fail to Top Monotherapy in MDS

(MedPage Today) May 10, 2017 - Two different combinations failed to improve response in high-risk myelodysplastic syndromes (MDS) compared with chemotherapy alone, a randomized trial showed.

read article (free registration required)
Next Page